The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020
Open accessAbstract
As of January 3, 2021, a total of 20,346,372 cases of coronavirus disease 2019 (COVID-19) and 349,246 associated deaths have been reported in the United States. Long-term sequalae of COVID-19 over the course of a lifetime currently are unknown; however, persistent symptoms and serious complications are being reported among COVID-19 survivors, including persons who initially experience a mild acute illness.* On December 11, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 vaccine to prevent COVID-19, administered as 2 doses separated by 21 days. On December 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine (1); initial doses were recommended for health care personnel and long-term care facility residents (2). As of December 23, 2020, a reported 1,893,360 first doses of Pfizer-BioNTech COVID-19 vaccine had been administered in the United States, and reports of 4,393 (0.2%) adverse events after receipt of Pfizer BioNTech COVID-19 vaccine had been submitted to the Vaccine Adverse Event Reporting System (VAERS). Among these, 175 case reports were identified for further review as possible cases of severe allergic reaction, including anaphylaxis. Anaphylaxis is a life-threatening allergic reaction that does occur rarely after vaccination, with onset typically within minutes to hours (3). Twenty-one cases were determined to be anaphylaxis (a rate of 11.1 per million doses administered), including 17 in persons with a documented history of allergies or allergic reactions, seven of whom had a history of anaphylaxis. The median interval from vaccine receipt to symptom onset was 13 minutes (range = 2-150 minutes). Among 20 persons with follow-up information available, all had recovered or been discharged home. Of the remaining case reports that were determined not to be anaphylaxis, 86 were judged to be nonanaphylaxis allergic reactions, and 61 were considered nonallergic adverse events. Seven case reports were still under investigation. This report summarizes the clinical and epidemiologic characteristics of case reports of allergic reactions, including anaphylaxis and nonanaphylaxis allergic reactions, after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine during December 14-23, 2020, in the United States. CDC has issued updated interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States (4) and interim considerations for preparing for the potential management of anaphylaxis (5). In addition to screening for contraindications and precautions before administering COVID-19 vaccines, vaccine locations should have the necessary supplies available to manage anaphylaxis, should implement postvaccination observation periods, and should immediately treat persons experiencing anaphylaxis signs and symptoms with intramuscular injection of epinephrine (4,5).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)
Shimabukuro, T. T., Nguyen, M., Martin, D., & DeStefano, F. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.07.035 · Cited by 608
Oliver, S. E., Gargano, J. W., Marin, M., Wallace, M., Curran, K. G., Chamberland, M., McClung, N., Campos-Outcalt, D., Morgan, R. L., Mbaeyi, S., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6950e2 · Cited by 536
Rüggeberg, J. U., Gold, M. S., Bayas, J.-M., Blum, M. D., Bonhoeffer, J., Friedlander, S., de Souza Brito, G., Heininger, U., Imoukhuede, B., Khamesipour, A., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.02.064 · Cited by 383
Rossen, L. M., Branum, A. M., Ahmad, F. B., Sutton, P., & Anderson, R. N. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6942e2 · Cited by 372
Dooling, K., McClung, N., Chamberland, M., Marin, Wallace, M., Bell, B. P., Lee, G. M., Talbot, H. K., Romero, J. R., & Oliver, S. E. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6949e1 · Cited by 311
Vaccine-associated hypersensitivity
McNeil, M. M., & DeStefano, F. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.12.971 · Cited by 273
The reporting sensitivities of two passive surveillance systems for vaccine adverse events.
Rosenthal, S., & Chen, R. (1995) · American Journal of Public Health · doi:10.2105/ajph.85.12.1706 · Cited by 201
Halsey, N. A., Griffioen, M. A., Dreskin, S. C., Dekker, C. L., Wood, R. J. K., Sharma, D., Jones, J. F., LaRussa, P. S., Garner, J., Berger, M., et al. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.09.066 · Cited by 61
Cited by
COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries
(2021) · doi:10.1038/s41591-021-01454-y · Cited by 1,105
Surveillance for Adverse Events After COVID-19 mRNA Vaccination
Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., Donahue, J. G., Kharbanda, E. O., Naleway, A., Nelson, J. C., et al. (2021) · JAMA · doi:10.1001/jama.2021.15072 · Cited by 626
Shi, D., Beasock, D., Fessler, A., Szebeni, J., Ljubimova, J. Y., Afonin, K. A., & Dobrovolskaia, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114079 · Cited by 535
Banerji, A., Wickner, P. G., Saff, R., Stone, C. A., Robinson, L. B., Long, A. A., Wolfson, A. R., Williams, P., Khan, D. A., Phillips, E., et al. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.12.047 · Cited by 452
BNT162b2 mRNA COVID-19 Vaccine: First Approval
Lamb, Y. N. (2021) · Drugs · doi:10.1007/s40265-021-01480-7 · Cited by 424
Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination
Beatty, A. L., Peyser, N. D., Butcher, X. E., Cocohoba, J. M., Lin, F., Olgin, J. E., Pletcher, M. J., & Marcus, G. M. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.40364 · Cited by 396
Watad, A., De Marco, G., Mahajna, H., Druyan, A., Eltity, M., Hijazi, N., Haddad, A., Elias, M., Zisman, D., Naffaa, M. E., et al. (2021) · Vaccines · doi:10.3390/vaccines9050435 · Cited by 363
Shimabukuro, T., & Nair, N. (2021) · JAMA · doi:10.1001/jama.2021.0600 · Cited by 325
mRNA vaccines for COVID-19: what, why and how
Park, J. W., Lagniton, P. N. P., Liu, Y., & Xu, R.-H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59233 · Cited by 321
Controlling the biodistribution and clearance of nanomedicines
Cabral, H., Li, J., Miyata, K., & Kataoka, K. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00138-1 · Cited by 303
Kadali, R. A. K., Janagama, R., Peruru, S., & Malayala, S. V. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.04.047 · Cited by 285
CDC COVID-19 Response Team, & Administration, F. A. D. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7004e1 · Cited by 269
Self-citationPadín-González, E., Lancaster, P., Bottini, M., Gasco, P., Tran, L., Fadeel, B., Wilkins, T., & Monopoli, M. P. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.882363 · Cited by 166
Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines
Moghimi, S. M. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.01.030 · Cited by 150
Chen, G., Li, X., Sun, M., Zhou, Y., Yin, M., Zhao, B., & Li, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669010 · Cited by 49
Histological and serological features of acute liver injury after SARS-CoV-2 vaccination
Codoni, G., Kirchner, T., Engel, B., Villamil, A. M., Efe, C., Stättermayer, A. F., Weltzsch, J. P., Sebode, M., Bernsmeier, C., Lleo, A., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2022.100605 · Cited by 37
General determination of causation between Covid-19 vaccines and possible adverse events
Hampton, L. M., Aggarwal, R., Evans, S. J. W., & Law, B. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.01.057 · Cited by 21
Metadata
- Authors
- CDC COVID-19 Response Team, & Administration, F. A. D.
- Venue
- MMWR. Morbidity and Mortality Weekly Report
- Published
- 2021-01-15
- Volume
- 70
- Issue
- 2
- Pages
- 46-51
- ISSN
- 0149-2195 (ISSN-L)
- 1545-861X
- OpenAlex
- W3120968995
- Cited by
- 479
- References
- 8
- FWCI
- 34.13
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.